PNC-27: A Novel Peptide Targeting Cancer Cell Membranes
Discover the groundbreaking research behind PNC-27, a peptide with selective anticancer properties.
Get a Quote & SampleProduct Core Value
Anticancer Peptide PNC-27
PNC-27 is a membrane-active peptide that exhibits selective cytotoxicity against cancer cells. It functions by binding to the HDM-2 protein, which is overexpressed on the membranes of various cancer cells. This binding induces the formation of transmembrane pores, leading to tumor cell necrosis without affecting normal cells. This targeted mechanism offers a promising approach for cancer treatment.
- Leveraging the power of peptide-based cancer treatment, PNC-27 offers a novel therapeutic strategy.
- Understanding the PNC-27 mechanism of action reveals its unique ability to target HDM-2 protein on cancer cell membranes.
- The selective cancer cell necrosis induced by PNC-27 marks a significant advancement in oncology research.
- This p53-independent cancer therapy approach bypasses common resistance mechanisms seen with other treatments.
Key Advantages
Targeted Action
PNC-27's precision in targeting cancer cells through HDM-2 interaction minimizes damage to healthy tissues, a crucial aspect of effective cancer treatment.
Mechanism of Cell Death
The induction of necrosis by PNC-27 provides a distinct pathway for eliminating cancer cells, differentiating it from apoptosis-inducing agents.
Broad Applicability
Research on PNC-27 indicates its efficacy against a wide range of cancer types, including various forms of leukemia, suggesting broad potential in PNC-27 research.
Key Applications
Leukemia Therapy
Exploring PNC-27 for leukemia treatment shows significant promise, offering a new avenue for patients unresponsive to conventional therapies.
Oncology Research
The study of PNC-27 contributes valuable insights into molecular mechanisms of cancer cell death and potential peptide-based cancer treatment strategies.
Targeted Drug Development
PNC-27's specific interaction with HDM-2 protein serves as a model for developing other targeted therapies in the field of oncology.
Cancer Cell Necrosis Induction
Understanding how PNC-27 induces selective cancer cell necrosis is vital for developing more effective and less toxic cancer treatments.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).